Skip to content

Multi-Center Randomized Controlled Clinical Trial of Sitz Bath Medications for Improving Symptoms After Hemorrhoidectomy

Multi-Center Randomized Controlled Clinical Trial of Sitz Bath Medications for Improving Symptoms After Hemorrhoidectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001198
Enrollment
Unknown
Registered
2025-06-17
Start date
2021-06-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

grades III/IV internal hemorrhoids mixed hemorrhoids or external hemorrhoids

Interventions

trial group:Postoperative routine wound care treatment + sitz bath with a mixture of 1.6g Tongxuekang capsules and 1000ml warm water at approximately 40°C, twice daily, for 15 minutes per session.
control group:Postoperative routine wound care treatment + sitz bath with a mixture of 30ml povidone-iodine and 1000ml warm water at approximately 40°C, twice daily, for 15 minutes per session.

Sponsors

Xiyuan Hospital of CACMS
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients clinically diagnosed with grade III or IV internal hemorrhoids mixed hemorrhoids or external hemorrhoids who have undergone surgical treatment and present with postoperative complications such as pain bleeding distension and wound edge edema; aged 18 to 75 years regardless of gender; with informed consent obtained from the patient or their guardian and a signed consent form.

Exclusion criteria

Exclusion criteria: Patients with poor prognosis such as those in the late stages of malignant tumors or with severe chronic diseases affecting various systems; patients diagnosed with other anorectal diseases; pregnant or breastfeeding women; individuals with poor compliance who are unable or unwilling to complete follow-up; patients with abnormal platelet levels abnormal renal function indicators or liver function indicators exceeding twice the normal range; individuals with allergic constitutions a history of drug or food allergies or known allergies to the components of the study medication; those who have participated in other clinical trials within the past three months; and other conditions deemed unsuitable for inclusion by the researchers.

Design outcomes

Primary

MeasureTime frame
Degree of Anal Wound Edge Edema;Bleeding Condition;Wound Healing Degree;Anal Pain Score;Anal Heaviness or Sensation of Fullness;

Secondary

MeasureTime frame
Complete Blood Count;Liver Function;Renal Function;

Countries

China

Contacts

Public Contactxiezheninan

Xiyuan Hospital of CACMS

xiezhennian@163.com13401185869

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026